Teva Pharmaceuticals has filed a complaint against Mylan, a generic drug maker this week, alleging infringement of four patents covering Copaxone, Teva’s ethical drug for treating multiple sclerosis. Teva filed suit in the U.S. District Court for the Southern District of New York.
This is not the first time that Teva has sued Mylan over Copaxone. Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven “Orange Book” patents, covering the chemical composition of Copaxone, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.
We note that earlier this month, Teva managed to block generic Copaxone manufactured by Sandoz and Momenta Pharmaceuticals by obtaining a district court injunction.